RT Journal Article
SR Electronic
T1 Impaired cellular immunity to SARS-CoV-2 in severe COVID-19 patients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.08.10.20171371
DO 10.1101/2020.08.10.20171371
A1 Ni, Ling
A1 Cheng, Meng-Li
A1 Zhao, Hui
A1 Feng, Yu
A1 Liu, Jingyuan
A1 Ye, Fang
A1 Ye, Qing
A1 Zhu, Gengzhen
A1 Li, Xiaoli
A1 Wang, Pengzhi
A1 Shao, Jing
A1 Deng, Yong-Qiang
A1 Wei, Peng
A1 Chen, Fang
A1 Qin, Cheng-Feng
A1 Wang, Guoqing
A1 Li, Fan
A1 Zeng, Hui
A1 Dong, Chen
YR 2020
UL http://medrxiv.org/content/early/2020/08/12/2020.08.10.20171371.abstract
AB The World Health Organization has declared SARS-CoV-2 virus outbreak a world-wide pandemic. Individuals infected by the virus exhibited different degrees of symptoms, the basis of which remains largely unclear. Currently, though convalescent individuals have been shown with both cellular and humoral immune responses, there is very limited understanding on the immune responses, especially adaptive immune responses, in patients with severe COVID-19. Here, we examined 10 blood samples from COVID-19 patients with acute respiratory distress syndrome (ARDS). The majority of them (70%) mounted SARS-CoV-2-specific humoral immunity with production of neutralizing antibodies. However, compared to healthy controls, the percentages and absolute numbers of both NK cells and CD8+ T cells were significantly reduced, accompanied with decreased IFNγ expression in CD4+ T cells in peripheral blood from severe patients. Most notably, we failed in detecting SARS-CoV-2-specific IFNγ production by peripheral blood lymphocytes from these patients. Our work thus indicates that COVID-19 patients with severe symptoms are associated with defective cellular immunity, which not only provides insights on understanding the pathogenesis of COVID-19, but also has implications in developing an effective vaccine to SARS-CoV-2.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported in part by grants from the National Key Research and Development Program of China (2016YFC0906200 to CD, 2016YFC130390 to LN , and 2020YFA0707800 to XW), Natural Science Foundation of China (31991173, 31821003 and 31991170 to CD), Beijing Municipal Science and Technology (Z181100001318007, Z181100006318015 and Z171100000417005 to C.D.), Zhejiang University Foundation (2020XGZX014 to CD), Tsinghua University (to CD) and Science and Technology Development Plan Project of Jilin Province (20200901007SF to F.L.).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institution review board of Tsinghua Univeristy Project title" Detection of virus-specific antibodies and CTL in patients with COVID-19" was approved on Feb 26,2020.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesall the data referred to in the manuscript are available.